BACKGROUND: Patients with severely reduced left-ventricular ejection fraction carry a high risk of morbidity and mortality after cardiac surgery. Levosimendan can be used prophylactically in these patients having shown positive effects on short-term outcome. However, effects on long-term outcome and patient subgroups benefiting the most are unknown. We aim to address these topics with real-life data from our clinical practice. METHODS: Two hundred eigthy eight patients with preoperative LVEF
Grieshaber, P.; Lipp, S.; Arnold, A.; Gorlach, G.; Wollbruck, M.; Roth, P.; Niemann, B.; Wilhelm, J.; Boning, A.
Keywords
- Aged
- Aged, 80 and over
- Atrial Fibrillation/chemically induced
- Cardiopulmonary Bypass
- Cardiotonic Agents/adverse effects/*therapeutic use
- Coronary Artery Bypass/*adverse effects/mortality
- Female
- Humans
- Hydrazones/adverse effects/*therapeutic use
- Kidney/drug effects/physiology
- Male
- Middle Aged
- Postoperative Complications/etiology/*prevention & control
- Pyridazines/adverse effects/*therapeutic use
- Retrospective Studies
- Risk Factors
- Stroke Volume
- Time Factors
- Treatment Outcome
- Ventricular Dysfunction, Left/*complications/physiopathology
- Cardiac surgery
- High-risk patients
- Levosimendan
- Low cardiac output syndrome
